FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3022551803> ?p ?o ?g. }

• W3022551803 abstract "You have accessJournal of UrologyProstate Cancer: Basic Research & Pathophysiology I (MP16)1 Apr 2020MP16-13 INCREASED EXPRESSION OF MUTATED BRCA2 IS ASSOCIATED WITH POOR PROGNOSIS OF PATIENTS WITH HIGH RISK PROSTATE CANCER TREATED WITH DEFINITIVE RADIOTHERAPY Hiromichi Iwamura*, Jun Ito, Jotaro Mikami, Kazue Ise, Yuki Kohada, Go Anan, Mabumi Matsushita, Yasuhiro Kaiho, Chikara Ohyama, Yasuhiro Nakamura, and Makoto Sato Hiromichi Iwamura*Hiromichi Iwamura* More articles by this author , Jun ItoJun Ito More articles by this author , Jotaro MikamiJotaro Mikami More articles by this author , Kazue IseKazue Ise More articles by this author , Yuki KohadaYuki Kohada More articles by this author , Go AnanGo Anan More articles by this author , Mabumi MatsushitaMabumi Matsushita More articles by this author , Yasuhiro KaihoYasuhiro Kaiho More articles by this author , Chikara OhyamaChikara Ohyama More articles by this author , Yasuhiro NakamuraYasuhiro Nakamura More articles by this author , and Makoto SatoMakoto Sato More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000000841.013AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: PARP inhibitor shows activity in metastatic castration-resistant prostate cancer (PC) with BRCA mutation, however, the association of the BRCA mutation with treatment outcome of localized PC remains unclear. We aimed to investigate the prognostic significance of tumor BRCA2 mutation in patients with localized PC treated with radiotherapy (RT). METHODS: We retrospectively reviewed 174 patients with localized PC who received definitive RT between 2007-2017 and performed immunohistochemistry of mutated BRCA2 (mBRCA2) on their needle biopsy specimens. Positive expression of the mBRCA2 was defined as more than 10% of positive tumor cells. Kaplan-Meier method and multivariate Cox-regression analysis were performed to assess the impact of mBRCA2 expression on biochemical recurrence-free survival (BCR-FS) after RT. RESULTS: The median age, RT dose, and follow-up period were 72 years, 74 Gy, and 54 months. 104 (60%) patients were D’Amico high risk. 53 (31%) patients showed positive expression of mBRCA2. The mBRCA2 expression was not associated with initial prostate-specific antigen, gleason score, clinical T stage, and D’Amico risk. Kaplan-Meier analysis showed that BCR-FS was not different according to the mBRCA2 expression, whereas, for high risk patients, significantly shorter BCR-FS was observed in patients with positive mBRCA2 expression compared to those with negative mBRCA2 expression (P = 0.035; Log-rank, 68% vs 91% at 5 year). Multivariate Cox-regression analysis revealed that positive expression of the mBRCA2 was an independent risk factor for BCR after RT only in high risk cohort (HR 2.77, P = 0.043). CONCLUSIONS: Increased expression of the mBRCA2 identified patients at high risk of BCR after definitive RT. Our results may allow to select potential candidate for PARP inhibitors as a combination therapy with RT. Source of Funding: None © 2020 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 203Issue Supplement 4April 2020Page: e220-e220 Advertisement Copyright & Permissions© 2020 by American Urological Association Education and Research, Inc.MetricsAuthor Information Hiromichi Iwamura* More articles by this author Jun Ito More articles by this author Jotaro Mikami More articles by this author Kazue Ise More articles by this author Yuki Kohada More articles by this author Go Anan More articles by this author Mabumi Matsushita More articles by this author Yasuhiro Kaiho More articles by this author Chikara Ohyama More articles by this author Yasuhiro Nakamura More articles by this author Makoto Sato More articles by this author Expand All Advertisement PDF downloadLoading ..." @default.
• W3022551803 created "2020-05-13" @default.
• W3022551803 creator A5000354865 @default.
• W3022551803 creator A5000448586 @default.
• W3022551803 creator A5017452074 @default.
• W3022551803 creator A5026851052 @default.
• W3022551803 creator A5027931145 @default.
• W3022551803 creator A5033726365 @default.
• W3022551803 creator A5034099267 @default.
• W3022551803 creator A5054771915 @default.
• W3022551803 creator A5076273759 @default.
• W3022551803 creator A5081925699 @default.
• W3022551803 creator A5090501626 @default.
• W3022551803 date "2020-04-01" @default.
• W3022551803 modified "2023-09-27" @default.
• W3022551803 title "MP16-13 INCREASED EXPRESSION OF MUTATED BRCA2 IS ASSOCIATED WITH POOR PROGNOSIS OF PATIENTS WITH HIGH RISK PROSTATE CANCER TREATED WITH DEFINITIVE RADIOTHERAPY" @default.
• W3022551803 doi "https://doi.org/10.1097/ju.0000000000000841.013" @default.
• W3022551803 hasPublicationYear "2020" @default.
• W3022551803 type Work @default.
• W3022551803 sameAs 3022551803 @default.
• W3022551803 citedByCount "0" @default.
• W3022551803 crossrefType "journal-article" @default.
• W3022551803 hasAuthorship W3022551803A5000354865 @default.
• W3022551803 hasAuthorship W3022551803A5000448586 @default.
• W3022551803 hasAuthorship W3022551803A5017452074 @default.
• W3022551803 hasAuthorship W3022551803A5026851052 @default.
• W3022551803 hasAuthorship W3022551803A5027931145 @default.
• W3022551803 hasAuthorship W3022551803A5033726365 @default.
• W3022551803 hasAuthorship W3022551803A5034099267 @default.
• W3022551803 hasAuthorship W3022551803A5054771915 @default.
• W3022551803 hasAuthorship W3022551803A5076273759 @default.
• W3022551803 hasAuthorship W3022551803A5081925699 @default.
• W3022551803 hasAuthorship W3022551803A5090501626 @default.
• W3022551803 hasBestOaLocation W30225518031 @default.
• W3022551803 hasConcept C121608353 @default.
• W3022551803 hasConcept C126322002 @default.
• W3022551803 hasConcept C143998085 @default.
• W3022551803 hasConcept C204232928 @default.
• W3022551803 hasConcept C2776235491 @default.
• W3022551803 hasConcept C2780192828 @default.
• W3022551803 hasConcept C509974204 @default.
• W3022551803 hasConcept C71924100 @default.
• W3022551803 hasConceptScore W3022551803C121608353 @default.
• W3022551803 hasConceptScore W3022551803C126322002 @default.
• W3022551803 hasConceptScore W3022551803C143998085 @default.
• W3022551803 hasConceptScore W3022551803C204232928 @default.
• W3022551803 hasConceptScore W3022551803C2776235491 @default.
• W3022551803 hasConceptScore W3022551803C2780192828 @default.
• W3022551803 hasConceptScore W3022551803C509974204 @default.
• W3022551803 hasConceptScore W3022551803C71924100 @default.
• W3022551803 hasIssue "Supplement 4" @default.
• W3022551803 hasLocation W30225518031 @default.
• W3022551803 hasOpenAccess W3022551803 @default.
• W3022551803 hasPrimaryLocation W30225518031 @default.
• W3022551803 hasRelatedWork W1980245127 @default.
• W3022551803 hasRelatedWork W2098154216 @default.
• W3022551803 hasRelatedWork W2106003470 @default.
• W3022551803 hasRelatedWork W2129122136 @default.
• W3022551803 hasRelatedWork W2150391295 @default.
• W3022551803 hasRelatedWork W2321033326 @default.
• W3022551803 hasRelatedWork W2350150832 @default.
• W3022551803 hasRelatedWork W2433835599 @default.
• W3022551803 hasRelatedWork W3029905168 @default.
• W3022551803 hasRelatedWork W3032252569 @default.
• W3022551803 hasVolume "203" @default.
• W3022551803 isParatext "false" @default.
• W3022551803 isRetracted "false" @default.
• W3022551803 magId "3022551803" @default.
• W3022551803 workType "article" @default.